## **Core Concept**
The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) as the first-line treatment for uncomplicated Plasmodium falciparum malaria. ACTs combine artemisinin or one of its derivatives with another antimalarial drug to improve efficacy and prevent resistance.

## **Why the Correct Answer is Right**
Artemether-lumefantrine, dihydroartemisinin-piperaquine, and artesunate-amodiaquine are all WHO-recommended ACTs. However, artesunate-mefloquine is not universally recommended due to concerns about mefloquine resistance and side effects in certain regions.

## **Why Each Wrong Option is Incorrect**
* **Option A:** Artemether-lumefantrine is a WHO-recommended ACT, effective against uncomplicated falciparum malaria.
* **Option B:** Dihydroartemisinin-piperaquine is another recommended ACT, known for its efficacy and relatively good safety profile.
* **Option C:** Artesunate-amodiaquine is also recommended by the WHO for the treatment of uncomplicated P. falciparum malaria.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the choice of ACT can depend on factors like local resistance patterns, side effect profiles, and the patient's ability to tolerate certain medications. The WHO regularly updates its guidelines to reflect the latest evidence on antimalarial treatments.

## **Correct Answer:** . Artesunate-Mefloquine